CoChat

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181, p-tau217 and p-tau231 measured using 10 assays to detect abnormal brain amyloid-β (Aβ) status and predict future progression to Alzheimer's dementia. The study included 135 patients with baseline diagnosis of mild cognitive impairment (mean age 72.4 years; 60.7% women) who were followed for an average of 4.9 years. Seventy-one participants had abnormal Aβ-status (i.e. abnormal CSF Aβ42/40) at baseline; and 45 of these Aβ-positive participants progressed to Alzheimer's dementia during follow-up. P-tau concentrations were determined in baseline plasma and CSF. P-tau217 and p-tau181 were both measured using immunoassays developed by Lilly Research Laboratories (Lilly) and mass spectrometry assays developed at Washington University (WashU). P-tau217 was also analysed using Simoa immunoassay developed by Janssen Research and Development (Janss). P-tau181 was measured using Simoa immunoassay from ADxNeurosciences (ADx), Lumipulse immunoassay from Fujirebio (Fuji) and Splex immunoassay from Mesoscale Discovery (Splex). Both p-tau181 and p-tau231 were quantified using Simoa immunoassay developed at the University of Gothenburg (UGOT). We found that the mass spectrometry-based p-tau217 (p-tau217WashU) exhibited significantly better performance than all other plasma p-tau biomarkers when detecting abnormal Aβ status [area under curve (AUC) = 0.947; Pdiff < 0.015] or progression to Alzheimer's dementia (AUC = 0.932; Pdiff < 0.027). Among immunoassays, p-tau217Lilly had the highest AUCs (0.886–0.889), which was not significantly different from the AUCs of p-tau217Janss, p-tau181ADx and p-tau181WashU (AUCrange 0.835–0.872; Pdiff > 0.09), but higher compared with AUC of p-tau231UGOT, p-tau181Lilly, p-tau181UGOT, p-tau181Fuji and p-tau181Splex (AUCrange 0.642–0.813; Pdiff ≤ 0.029). Correlations between plasma and CSF values were strongest for p-tau217WashU (R = 0.891) followed by p-tau217Lilly (R = 0.755; Pdiff = 0.003 versus p-tau217WashU) and weak to moderate for the rest of the p-tau biomarkers (Rrange 0.320–0.669). In conclusion, our findings suggest that among all tested plasma p-tau assays, mass spectrometry-based measures of p-tau217 perform best when identifying mild cognitive impairment patients with abnormal brain Aβ or those who will subsequently progress to Alzheimer's dementia. Several other assays (p-tau217Lilly, p-tau217Janss, p-tau181ADx and p-tau181WashU) showed relatively high and consistent accuracy across both outcomes. The results further indicate that the highest performing assays have performance metrics that rival the gold standards of Aβ-PET and CSF. If further validated, our findings will have significant impacts in diagnosis, screening and treatment for Alzheimer's dementia in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awac333

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 ROC curve analysis for abnormal CSF Aβ42/40 status and progression to ADD. ROC curve analysis for differentiating (A) MCI participants with abnormal CSF Aβ42/40 from those with normal CSF Aβ42/40 and (B) MCI patients who progressed to ADD during follow-up from those who did not (stable MCI patients and MCI patients who progressed to other types of dementia).
Figure 1 ROC curve analysis for abnormal CSF Aβ42/40 status and progression to ADD. ROC curve analysis for differentiating (A) MCI participants with abnormal CSF Aβ42/40 from those with normal CSF Aβ42/40 and (B) MCI patients who progressed to ADD during follow-up from those who did not (stable MCI patients and MCI patients who progressed to other types of dementia).CC BY-NC · PubMed Central
Figure 2 Plasma p-tau biomarkers in amyloid-negative and -positive MCI patients. Plasma levels of p-tau217 (A–C), p-tau181 (D–E and G–J) and p-tau231 (F) measured using different assays in the A− and A+ MCI groups. Aβ status was defined based on the CSF Aβ42/40 ratio. Data are presented as a fold change from the mean of the A− MCI group. Two p-tau217WashU and p-tau217Janss outliers in the A+ group and one p-tau181ADx outlier in the A− group are not shown in A, C and D, but these data were included in the statistical analysis. F-values and P-values are from univariate general linear models adjusted for age and sex. Boxes show interquartile range, the horizontal lines are medians and the whiskers and outliers were plotted using the Tukey method.
Figure 2 Plasma p-tau biomarkers in amyloid-negative and -positive MCI patients. Plasma levels of p-tau217 (A–C), p-tau181 (D–E and G–J) and p-tau231 (F) measured using different assays in the A− and A+ MCI groups. Aβ status was defined based on the CSF Aβ42/40 ratio. Data are presented as a fold change from the mean of the A− MCI group. Two p-tau217WashU and p-tau217Janss outliers in the A+ group and one p-tau181ADx outlier in the A− group are not shown in A, C and D, but these data were included in the statistical analysis. F-values and P-values are from univariate general linear models adjusted for age and sex. Boxes show interquartile range, the horizontal lines are medians and the whiskers and outliers were plotted using the Tukey method.CC BY-NC · PubMed Central
Figure 3 Plasma p-tau biomarkers in MCI participants who progressed to ADD during follow-up and amyloid-negative and -positive non-progressors. Plasma levels of p-tau217 (A–C), p-tau181 (D–E and G–J) and p-tau231 (F) measured using different assays in patients with MCI who progressed to ADD during follow-up (MCI-ADD), A− and A+ non-progressor MCI patients. Aβ status was defined based on the CSF Aβ42/40 ratio. Data are presented as a fold change from the mean of the A− MCI group. Two p-tau217WashU and p-tau217Janss outliers in the MCI-ADD group and one p-tau181ADx outlier in the A− group are not shown in A, C and D, but these data were included in the statistical analysis. F-values and P-values are from univariate general linear models adjusted for age, sex and follow-up time. Boxes show interquartile range, the horizontal lines are medians and the whiskers and outliers were plotted using the Tukey method.
Figure 3 Plasma p-tau biomarkers in MCI participants who progressed to ADD during follow-up and amyloid-negative and -positive non-progressors. Plasma levels of p-tau217 (A–C), p-tau181 (D–E and G–J) and p-tau231 (F) measured using different assays in patients with MCI who progressed to ADD during follow-up (MCI-ADD), A− and A+ non-progressor MCI patients. Aβ status was defined based on the CSF Aβ42/40 ratio. Data are presented as a fold change from the mean of the A− MCI group. Two p-tau217WashU and p-tau217Janss outliers in the MCI-ADD group and one p-tau181ADx outlier in the A− group are not shown in A, C and D, but these data were included in the statistical analysis. F-values and P-values are from univariate general linear models adjusted for age, sex and follow-up time. Boxes show interquartile range, the horizontal lines are medians and the whiskers and outliers were plotted using the Tukey method.CC BY-NC · PubMed Central
Figure 4 Correlations between CSF and plasma p-tau. Heat map showing Spearman coefficients for correlations between CSF and plasma p-tau measured using different assays (p-tau181UGOT, n = 72; p-tau181Splex, n = 52; all other biomarkers n = 78). Correlations between plasma and CSF p-tau measured with the same assay are highlighted in orange except plasma p-tau181Lilly and p-tau181Splex for which corresponding CSF assay data were not available.
Figure 4 Correlations between CSF and plasma p-tau. Heat map showing Spearman coefficients for correlations between CSF and plasma p-tau measured using different assays (p-tau181UGOT, n = 72; p-tau181Splex, n = 52; all other biomarkers n = 78). Correlations between plasma and CSF p-tau measured with the same assay are highlighted in orange except plasma p-tau181Lilly and p-tau181Splex for which corresponding CSF assay data were not available.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Team, 2014, R: A Language and Environment for Statistical Computing

Cited by

See all 522

Metadata

Authors
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., Pontecorvo, M. J., Zetterberg, H., Kolb, H., Vandijck, M., Blennow, K., Bateman, R. J., & Hansson, O.
Affiliations
  • Lund University (SE)
  • King's College London (GB)
  • Washington University in St. Louis (US)
  • ADx NeuroSciences (BE)
  • Neuroscience Biomarkers, Janssen Research & Development , La Jolla, CA , USA
  • Eli Lilly (United States) (US)
  • Sahlgrenska University Hospital (SE)
  • Janssen Research & Development (United States) (US)
  • Fujirebio (Belgium) (BE)
Corresponding author
Hansson, Oskar
Venue
Brain
Published
2022-09-10
Volume
146
Issue
4
Pages
1592-1601
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4295107480
Cited by
522
References
35
Citations by year
2026: 118 · 2025: 173 · 2024: 155 · 2023: 70 · 2022: 5
FWCI
65.53
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Swedish Research Council
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
  • Skåne University Hospital
  • Alzheimer Drug Discovery Foundation
  • Joint Programme – Neurodegenerative Disease Research
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
p-tau181, p-tau217, p-tau231, Alzheimer's disease, prodromal Alzheimer's disease, mild cognitive impairment, blood biomarkers, immunoassay comparison, mass spectrometry assay
MeSH terms
Aged, Alzheimer Disease, Brain, Female, Humans, Male, Biomarkers, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.